Qui Tam Litigation: Peter Rost Suit Fails As Others Thrive
Executive Summary
While whistleblowers have been scoring big payouts in suits alleging off-label promotion and kickbacks, Peter Rost struck out in his seven-year suit against Pfizer.
You may also be interested in...
Rapamune Whistleblower Suit Gets Jolt From Government Intervention
The Department of Justice has intervened in a qui tam suit alleging Wyeth promoted the immunosuppressant for off-label uses and offered kickbacks to providers. Settlement now seems more likely.
Forest Admits To Knowingly Obstructing FDA Inspection In Guilty Pleas On Levothroid, Celexa Marketing
Forest Pharmaceuticals reached a $313 million settlement with the Department of Justice to resolve criminal charges of obstructing an FDA inspection and distributing a misbranded drug and civil False Claims Act allegations.
Health Care Fraud Investigations Bedevil Pharma Industry: If You're Not Under Investigation, It's Only Because You've Recently Settled
Two months ago, the Department of Justice held a splashy news conference to announce its record-breaking $2.3 billion settlement with Pfizer. The event, which included HHS Secretary Kathleen Sebelius, cast a spotlight on Pfizer's alleged off-label marketing and kickbacks to health care providers (1"The Pink Sheet," Sept. 7, 2009)